Carregant...
Perspective on the role of Ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedema
Diabetic macular oedema (DMO) is the most common cause of visual loss in the working age population. Intravitreal therapy has superseded macular laser as the first-line treatment for the management of centre-involving DMO in most patients. As well as the proven efficacy of intravitreal anti-vascular...
Guardat en:
| Publicat a: | Ther Adv Chronic Dis |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4549694/ https://ncbi.nlm.nih.gov/pubmed/26336592 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040622315590319 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|